Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,395 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV. Kumar S, et al. Among authors: wolf j. Blood. 2012 May 10;119(19):4375-82. doi: 10.1182/blood-2011-11-395749. Epub 2012 Mar 15. Blood. 2012. PMID: 22422823 Free article. Clinical Trial.
Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
Bensinger WI, Jagannath S, Vescio R, Camacho E, Wolf J, Irwin D, Capo G, McKinley M, Potts P, Vesole DH, Mazumder A, Crowley J, Becker P, Hilger J, Durie BG. Bensinger WI, et al. Among authors: wolf j. Br J Haematol. 2010 Feb;148(4):562-8. doi: 10.1111/j.1365-2141.2009.07981.x. Epub 2009 Nov 16. Br J Haematol. 2010. PMID: 19919652 Free article. Clinical Trial.
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.
Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, Fonseca R, Stewart AK, Harousseau JL, Dimopoulos M, Jagannath S, Hajek R, Sezer O, Kyle R, Sonneveld P, Cavo M, Rajkumar SV, San Miguel J, Crowley J, Avet-Loiseau H; International Myeloma Workshop Consensus Panel 2. Munshi NC, et al. Blood. 2011 May 5;117(18):4696-700. doi: 10.1182/blood-2010-10-300970. Epub 2011 Feb 3. Blood. 2011. PMID: 21292777 Free PMC article.
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.
Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, Sougnez C, Knoechel B, Gould J, Saksena G, Cibulskis K, McKenna A, Chapman MA, Straussman R, Levy J, Perkins LM, Keats JJ, Schumacher SE, Rosenberg M; Multiple Myeloma Research Consortium; Getz G, Golub TR. Lohr JG, et al. Cancer Cell. 2014 Jan 13;25(1):91-101. doi: 10.1016/j.ccr.2013.12.015. Cancer Cell. 2014. PMID: 24434212 Free PMC article.
Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.
Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, Dumontet C, Dudziński M, Fejerman L, Greenberg A, Huntsman S, Jamroziak K, Jurczyszyn A, Kumar S, Atanackovic D, Glenn M, Cannon-Albright LA, Jones B, Lee A, Marques H, Martin T, Martinez-Lopez J, Rajkumar V, Sainz J, Vangsted AJ, Wątek M, Wolf J, Slager S, Camp NJ, Canzian F, Vachon C. Ziv E, et al. Among authors: wolf j. Nat Commun. 2015 Jul 22;6:7539. doi: 10.1038/ncomms8539. Nat Commun. 2015. PMID: 26198393 Free PMC article.
TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.
Ghobrial IM, Siegel DS, Vij R, Berdeja JG, Richardson PG, Neuwirth R, Patel CG, Zohren F, Wolf JL. Ghobrial IM, et al. Am J Hematol. 2016 Jun;91(4):400-5. doi: 10.1002/ajh.24300. Am J Hematol. 2016. PMID: 26800393 Free article. Clinical Trial.
4,395 results